Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests focused on non-invasive detection of high-mortality cancers in high-risk patient populations, received accreditation for its clinical laboratory from the College of American Pathologists (CAP).
For the full article click here: Bluestar Genomics Receives CAP Accreditation for Its Clinical Laboratory | AP NEWS